Gilead Sciences Q1 EPS Estimate Raised by Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Zacks Research upped their Q1 2025 earnings estimates for shares of Gilead Sciences in a research report issued to clients and investors on Tuesday, February 25th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will earn $1.72 per share for the quarter, up from their previous estimate of $1.65. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q2 2025 earnings at $1.92 EPS, Q3 2025 earnings at $2.06 EPS, Q4 2025 earnings at $2.03 EPS, FY2025 earnings at $7.74 EPS, Q1 2026 earnings at $1.69 EPS, Q2 2026 earnings at $1.83 EPS, Q4 2026 earnings at $2.24 EPS, FY2026 earnings at $7.96 EPS and FY2027 earnings at $8.58 EPS.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%.

Several other equities analysts have also weighed in on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Mizuho upped their price objective on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. UBS Group raised their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Wolfe Research initiated coverage on Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $102.08.

Gilead Sciences Trading Down 1.0 %

Shares of GILD stock opened at $110.46 on Thursday. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $112.11. The stock has a market cap of $137.66 billion, a price-to-earnings ratio of 298.54, a PEG ratio of 0.71 and a beta of 0.18. The company’s 50-day moving average price is $96.56 and its 200-day moving average price is $89.49. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp raised its position in shares of Gilead Sciences by 1.4% during the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after acquiring an additional 841,776 shares in the last quarter. FMR LLC increased its stake in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP raised its holdings in Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock worth $3,293,822,000 after purchasing an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock worth $2,608,337,000 after buying an additional 749,047 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $1,789,254,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 542,001 shares of company stock valued at $52,230,551. Insiders own 0.16% of the company’s stock.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.86%. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.